In the 21st century, thanks to advances in biotechnology and developing pharmaceutical technology, significant progress is being made in effective drug design. Drug targeting aims to ensure that the drug acts only in the pathological area; it is defined as the ability to accumulate selectively and quantitatively in the target tissue or organ, regardless of the chemical structure of the active drug substance and the method of administration. With drug targeting, conventional, biotechnological and gene-derived drugs target the body’s organs, tissues, and cells that can be selectively transported to specific regions. These systems serve as drug carriers and regulate the timing of release. Despite having many advantageous features, these systems have limitations in thoroughly treating complex diseases such as cancer. Therefore, combining these systems with nanoparticle technologies is imperative to treat cancer at both local and systemic levels effectively. The nanocarrier-based drug delivery method involves encapsulating target-specific drug molecules into polymeric or vesicular systems. Various drug delivery systems (DDS) were investigated and discussed in this review article. The first part discussed active and passive delivery systems, hydrogels, thermoplastics, microdevices and transdermal-based drug delivery systems. The second part discussed drug carrier systems in nanobiotechnology (carbon nanotubes, nanoparticles, coated, pegylated, solid lipid nanoparticles and smart polymeric nanogels). In the third part, drug targeting advantages were discussed, and finally, market research of commercial drugs used in cancer nanotechnological approaches was included.

Metal‐organic frameworks (MOFs) represent a highly promising material class for bioelectronic supercapacitors, characterized by their adjustable structures, extensive surface areas, and superior electrochemical properties. This research explores the synthesis and incorporation of MOF‐based materials into bioelectronic devices aimed at energy storage and biosensing applications. The focus is on improving the electrochemical performance of MOFs while preserving their structural integrity through functionalization with biocompatible polymers and conductive materials. The resulting MOF‐based bioelectronic supercapacitors exhibit significant improvements in specific capacitance, energy density, and cycling stability. Additionally, the inclusion of bioreceptors allows for the simultaneous detection of biochemical signals alongside energy storage, thus enabling innovative applications in wearable electronics and health monitoring systems. These results suggest that MOF‐based supercapacitors have the capacity to fulfill energy storage needs while also advancing bioelectronics by merging energy and sensing capabilities.